Kyverna Therapeutics, Inc. (KYTX) Stock

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, specializes in advancing innovative cell therapies tailored for patients grappling with autoimmune diseases. At the forefront of its development pipeline is KYV-101, an autologous CD19 CAR T-cell product candidate currently undergoing Phase I clinical trials for lupus nephritis and systemic sclerosis, and Phase II trials for myasthenia gravis and multiple sclerosis.

Additionally, Kyverna Therapeutics is progressing KYV-201, an allogeneic CD19 CAR T-cell product candidate in the preclinical stage aimed at treating multiple autoimmune disorders. The company's robust pipeline extends to include therapies targeting inflammatory bowel diseases like Crohn's disease and ulcerative colitis.

Established in 2018 and headquartered in Emeryville, California, Kyverna Therapeutics, Inc. was previously known as BAIT Therapeutics, Inc., rebranding in October 2019 to reflect its expanded focus and strategic vision. The company operates with a license and collaboration agreement with Intellia Therapeutics, Inc. for the research and development of allogeneic CD19-directed CAR cell therapy products, as well as a partnership with Kite focused on advancing programs for autoimmune, inflammatory, and stem cell transplant inflammatory diseases.